Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report

Despite the success of anti-<i>BRAF</i> therapy in melanoma, data from randomized clinical trials are lacking for targeted therapy against <i>BRAF</i> mutations-typically the V600E variant-in pancreatic adenocarcinoma, which is associated with a poor prognosis under traditional cytotoxic chemotherapy. Here, we report a case of an elderly patient with advanced pancreatic adenocarcinoma harboring a <i>BRAF</i> V600E mutation who received low-dose dabrafenib and trametinib and achieved satisfactory clinical outcomes. We describe a 78-year-old female with <i>BRAF</i> V600E-mutant pancreatic adenocarcinoma. The patient was diagnosed with AJCC clinical stage IV (cT3N2M1) pancreatic adenocarcinoma and she declined chemotherapy because of her advanced age. Owing to the <i>BRAF</i> V600E mutation, the patient was started on combined <i>BRAF</i>- and <i>MEK</i> inhibitors (dabrafenib/trametinib). CT scans showed PR on 31 December 31, 2024, and repeated CT scans showed SD on May 2025. At the time of drafting this report, the patient had achieved 8 months of PFS. This case suggests that dose-adjusted dabrafenib combined with trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring <i>BRAF</i> V600E mutations.